A multicenter study has developed a predictive model to help identify pancreatic cancer patients who are unlikely to benefit from surgery after neoadjuvant therapy.
The research focuses on pancreatic ductal adenocarcinoma patients who receive chemotherapy before surgery. Although this approach can improve outcomes, about 24% of patients still experience very poor results after surgery, with recurrence or death within six months. The new model aims to flag these high-risk cases earlier.
The tool uses six factors measured after chemotherapy but before surgery, including bilirubin levels, tumor size, CA19-9 changes, overall health status, albumin levels, and white blood cell counts. Together, these markers help estimate the likelihood of early treatment failure.
The model showed good accuracy in testing and is available as an online calculator for clinicians. Researchers say it could help avoid unnecessary surgery and guide patients toward better-suited treatment options, although further validation is still needed.